A new study from the Employee Benefit Research Institute (EBRI) Center for Research on Health Benefits Innovation, finds payments for infused cancer medicines in the commercial and employment-based markets are nearly two times higher in hospital outpatient departments (HOPD), relative to physician offices (PO), for the same drug. The Issue Brief, “Cost Differences for Oncology Medicines Based on Site of Treatment”, also finds these cost differences are due to the pricing decisions of hospitals, not differences in modality.
EBRI invites you to a webinar that will address these findings, explore actions that employers and third-party payers can take to lower patient costs, and more.
If you are interested in sponsoring one of our webinars, please contact us at firstname.lastname@example.org.
with Paul Fronstin, Lee Murphy, and Tami Simon